Serum D-2-hydroxyglutarate and the Ratio of D-2HG/L-2HG Predict Mutation in Acute Myeloid Leukemia

Overview

Journal EJHaem

Specialty Hematology

Date 2023 Aug 21

PMID 37601838

Authors

Chelsea Zhang

Andrew Chu

Richard Boriack

Robert Collins

Jing Xu

Dwight Oliver

Ruifang Zheng

Dinesh Rakheja

Weina Chen

Affiliations

Soon will be listed here.

Abstract

This study investigates whether serum D-2HG (D-2-hydroxyglutarate) produced by the mutated isocitrate dehydrogenase (IDH) can predict mutations in acute myeloid leukemia (AML) at diagnosis. D-2HG and L-2HG are measured by liquid chromatography-tandem mass spectrometry. D-2HG, total 2HG and the D/L ratio (D-2HG/L-2HG) are significantly higher in cases than in cases. The optimal cutoff values to predict mutations at 100% sensitivity (specificity 91%-94%) are >588 ng/mL for D-2HG and >2.33 for the D/L ratio. Our study indicates that elevated serum D-2HG and the D/L ratio may serve as noninvasive biomarkers of mutation in AML.

Citing Articles

A genetically encoded fluorescent sensor enables sensitive and specific detection of IDH mutant associated oncometabolite D-2-hydroxyglutarate.

Choate K, Konickson W, Moreno Z, Brill O, Cromell B, Detienne B BMC Cancer. 2025; 25(1):473.

PMID: 40087637 DOI: 10.1186/s12885-025-13877-8.

Exploration of the intracellular chiral metabolome in pediatric BCP-ALL: a pilot study investigating the metabolic phenotype of IgH locus aberrations.

Collins M, Gorgoglione R, Impedovo V, Pan X, Chakkarai S, Yi S Front Oncol. 2024; 14:1413264.

PMID: 39161381 PMC: 11332069. DOI: 10.3389/fonc.2024.1413264.

Serum D-2-hydroxyglutarate and the ratio of D-2HG/L-2HG predict mutation in acute myeloid leukemia.

Zhang C, Chu A, Boriack R, Collins R, Xu J, Oliver D EJHaem. 2023; 4(3):723-727.

PMID: 37601838 PMC: 10435681. DOI: 10.1002/jha2.723.

References

Gross S, Cairns R, Minden M, Driggers E, Bittinger M, Jang H . Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010; 207(2):339-44. PMC: 2822606. DOI: 10.1084/jem.20092506. View

Ward P, Patel J, Wise D, Abdel-Wahab O, Bennett B, Coller H . The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3):225-34. PMC: 2849316. DOI: 10.1016/j.ccr.2010.01.020. View

Ward P, Cross J, Lu C, Weigert O, Abel-Wahab O, Levine R . Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene. 2011; 31(19):2491-8. PMC: 3271133. DOI: 10.1038/onc.2011.416. View

Wang J, Chen W, Li J, Wu S, Chen T, Zhu Y . Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proc Natl Acad Sci U S A. 2013; 110(42):17017-22. PMC: 3801077. DOI: 10.1073/pnas.1315558110. View

Wiseman D, Struys E, Wilks D, Clark C, Dennis M, Jansen E . Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy. Leukemia. 2015; 29(12):2421-3. DOI: 10.1038/leu.2015.151. View

Mardis E, Ding L, Dooling D, Larson D, McLellan M, Chen K . Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361(11):1058-66. PMC: 3201812. DOI: 10.1056/NEJMoa0903840. View

Zhang C, Chu A, Boriack R, Collins R, Xu J, Oliver D . Serum D-2-hydroxyglutarate and the ratio of D-2HG/L-2HG predict mutation in acute myeloid leukemia. EJHaem. 2023; 4(3):723-727. PMC: 10435681. DOI: 10.1002/jha2.723. View

Dang L, White D, Gross S, Bennett B, Bittinger M, Driggers E . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462(7274):739-44. PMC: 2818760. DOI: 10.1038/nature08617. View

Jones P, Boriack R, Struys E, Rakheja D . Measurement of Oncometabolites D-2-Hydroxyglutaric Acid and L-2-Hydroxyglutaric Acid. Methods Mol Biol. 2017; 1633:219-234. DOI: 10.1007/978-1-4939-7142-8_14. View

10.

Figueroa M, Abdel-Wahab O, Lu C, Ward P, Patel J, Shih A . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6):553-67. PMC: 4105845. DOI: 10.1016/j.ccr.2010.11.015. View

11.

Janin M, Mylonas E, Saada V, Micol J, Renneville A, Quivoron C . Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol. 2013; 32(4):297-305. DOI: 10.1200/JCO.2013.50.2047. View

12.

DiNardo C, Propert K, Loren A, Paietta E, Sun Z, Levine R . Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013; 121(24):4917-24. PMC: 3682342. DOI: 10.1182/blood-2013-03-493197. View

13.

Shim E, Livi C, Rakheja D, Tan J, Benson D, Parekh V . L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov. 2014; 4(11):1290-8. PMC: 4286872. DOI: 10.1158/2159-8290.CD-13-0696. View

14.

Fathi A, Sadrzadeh H, Borger D, Ballen K, Amrein P, Attar E . Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012; 120(23):4649-52. DOI: 10.1182/blood-2012-06-438267. View

15.

Rakheja D, Konoplev S, Medeiros L, Chen W . IDH mutations in acute myeloid leukemia. Hum Pathol. 2012; 43(10):1541-51. DOI: 10.1016/j.humpath.2012.05.003. View

16.

Paschka P, Schlenk R, Gaidzik V, Habdank M, Kronke J, Bullinger L . IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010; 28(22):3636-43. DOI: 10.1200/JCO.2010.28.3762. View